A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Serelaxin (Primary)
- Indications Acute heart failure
- Focus Registrational; Therapeutic Use
- Acronyms RELAX AHF-Pan EU; RELAX-AHF-EU
- Sponsors Novartis Pharmaceuticals
- 12 Jul 2017 Status changed from recruiting to discontinued.
- 13 Jun 2017 This trial has been discontinued in Croatia (end date: 25 Apr 2017).
- 03 Jun 2017 This trial has been discontinued in Greece (End date:2017-04-28) and Slovakia as per European Clinical Trials Database record.